# Breakthrough Blood Test for Alzheimer’s Care

Newsy: Alzheimer’s News Weekly
Published: 2025-10-13T15:00:00.305Z
Source: https://newsyai.com/edition/01e9d986-ed04-47ff-8feb-03cae830270c
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# The Alzheimer’s Treatment Briefing
Weekly roundup of the most important developments in Alzheimer’s care and research  
Coverage period: October 7–13, 2025 (U.S.)

—

## Top stories (ranked)

1) FDA clears a primary‑care Alzheimer’s blood test that can quickly “rule out” disease
- What’s new  
  - On October 13, the FDA cleared Roche and Eli Lilly’s Elecsys pTau181 blood test for adults 55+ who come to primary care with memory concerns. In a 312‑person study, a negative result ruled out Alzheimer’s‑type brain changes with 97.9% accuracy. Because more than 4,500 Roche analyzers are already installed in U.S. labs, the test could roll out quickly. This is the second FDA‑cleared Alzheimer’s blood test, and the first specifically cleared for use in primary care to triage patients. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/) | [Roche announcement](https://www.roche.com/investors/updates/inv-update-2025-10-13b) ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai))
- Why this matters  
  - Faster answers with fewer referrals: A simple blood draw in primary care can quickly tell many people they’re unlikely to have Alzheimer’s‑type changes, sparing invasive spinal taps or costly PET scans.  
  - Smoother path to treatment: For those who still screen positive, doctors can prioritize confirmatory testing and talk sooner about disease‑slowing options like lecanemab (Leqembi) or donanemab (Kisunla). This can shorten time to care and make MRI and specialist capacity go further. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/) | [Roche announcement](https://www.roche.com/investors/updates/inv-update-2025-10-13b) ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai))

2) “Weight‑loss” drugs are about to read out in Alzheimer’s—what to know before the headlines
- What’s new  
  - Novo Nordisk is nearing results from two large Phase 3 trials testing semaglutide (the active ingredient in Ozempic/Wegovy) in early Alzheimer’s disease. These GLP‑1 drugs were designed for diabetes and obesity, but lab, imaging, and real‑world data suggest they might also calm brain inflammation and protect nerve cells. Timelines and expectations were laid out in a new report today. [Financial Times](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6) ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai))
- Why this matters  
  - A different path than plaque‑clearing antibodies: If semaglutide slows decline—even modestly—it could add a safer, easier‑to‑use option that works alongside current drugs, or for people who aren’t a fit for them. If results are negative, it will help narrow what really matters in Alzheimer’s biology. Either way, this is a pivotal moment to watch. [Financial Times](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6) ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai))

3) Context for the new blood test: earlier “first” and why coverage/rollout may be faster now
- What’s new  
  - The FDA’s first Alzheimer’s blood test (Fujirebio’s Lumipulse) was cleared in May. With Elecsys now cleared and compatible with widely deployed lab analyzers, availability and ordering from primary care could expand quickly. Analysts expect easier testing to boost appropriate use of disease‑slowing treatments. [Reuters background](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-clears-first-blood-test-detect-alzheimers-disease-2025-05-16/) | [Reuters on Elecsys](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/) ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-clears-first-blood-test-detect-alzheimers-disease-2025-05-16/?utm_source=openai))
- Why this matters  
  - “Test, then treat” becomes more practical: Primary‑care‑based rule‑out testing can reduce delays, lower costs, and help specialists focus on those who most need confirmatory scans and therapy discussions. That can translate to earlier, safer starts for eligible patients. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/) ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai))

—

## What this means in plain language

- A simple blood test at your doctor’s office could soon tell many people with memory worries that Alzheimer’s‑type brain changes are unlikely. That means fewer PET scans or spinal taps, and faster decisions about next steps. [Roche announcement](https://www.roche.com/investors/updates/inv-update-2025-10-13b) | [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/) ([roche.com](https://www.roche.com/investors/updates/inv-update-2025-10-13b?utm_source=openai))  
- Big trials of semaglutide (Ozempic/Wegovy) for Alzheimer’s are close to reporting. If they help, we may get a new, easier‑to‑use tool that works differently from today’s plaque‑clearing drugs. If they don’t, we learn what not to chase. Either outcome is valuable. [Financial Times](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6) ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai))

—

## Quick guidance for patients and caregivers this week

- Ask your primary‑care clinician about blood‑based testing  
  - When will Elecsys pTau181 be available at your health system? How will results guide referrals or confirmatory testing? [Roche announcement](https://www.roche.com/investors/updates/inv-update-2025-10-13b) ([roche.com](https://www.roche.com/investors/updates/inv-update-2025-10-13b?utm_source=openai))
- If you’re considering disease‑slowing therapy (Leqembi/Kisunla)  
  - Blood tests may help triage faster, but you’ll still need careful MRI safety checks and shared decision‑making with a specialist. [Reuters background](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-clears-first-blood-test-detect-alzheimers-disease-2025-05-16/) ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-clears-first-blood-test-detect-alzheimers-disease-2025-05-16/?utm_source=openai))
- For those watching GLP‑1 news  
  - Results are not out yet. If positive, expect your team to discuss how GLP‑1s might fit with or alongside current treatments; if negative, plans won’t change. [Financial Times](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6) ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai))

—

## Sources and further reading
- Reuters: Roche/Lilly Alzheimer’s blood test wins U.S. FDA clearance (Oct 13, 2025). https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/ ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai))  
- Roche investor update: Elecsys pTau181 cleared for primary care “rule‑out” use (Oct 13, 2025). https://www.roche.com/investors/updates/inv-update-2025-10-13b ([roche.com](https://www.roche.com/investors/updates/inv-update-2025-10-13b?utm_source=openai))  
- Financial Times analysis: GLP‑1 Alzheimer’s trials nearing results (Oct 13, 2025). https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6 ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai))  
- Reuters background: First FDA‑cleared Alzheimer’s blood test (May 16, 2025). https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-clears-first-blood-test-detect-alzheimers-disease-2025-05-16/ ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-clears-first-blood-test-detect-alzheimers-disease-2025-05-16/?utm_source=openai))

—

Want us to track the first semaglutide readouts, anti‑tau antibodies, or insurance coverage changes for blood tests in next week’s brief? Tell us what to add to the watchlist.
